title: [Non valvular atrial fibrillation: the place of the new anticoagulants].
abstract: Atrial fibrillation (AF) increases the risk of mortality and stroke. The prevention of these complications is based on oral anticoagulants that are more efficient than salycilates. As compared with antivitamins K agents, new oral anticoagulants are promising for patients presenting non valvular atrial fibrillation because of lower cerebral hemorragic risk (with respect of assessment of renal function and therapeutic compliance). Available studies and recommendations are presented.
authors.forename: T
authors.initials: T
authors.lastname: Pepersack
mesh_terms: D015110:4-Hydroxycoumarins / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006801:Humans; D007192:Indenes / Q000627:therapeutic use; D020521:Stroke / Q000517:prevention & control; D014812:Vitamin K / Q000037:antagonists & inhibitors / Q000627:therapeutic use
chemical_list: D015110:4-Hydroxycoumarins; D000925:Anticoagulants; D015507:Drugs, Investigational; D007192:Indenes; C011664:antivitamins K; D014812:Vitamin K